{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:47:08Z","timestamp":1788497228454,"version":"build-2803163510"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03352-y","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T07:01:51Z","timestamp":1726297311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The role of IL-17 and Th17 cells in keloid pathogenesis"],"prefix":"10.1007","volume":"316","author":[{"given":"David","family":"Bitterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Kabakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paras","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Joerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Jagdeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"3352_CR1","doi-asserted-by":"crossref","unstructured":"Mony MP et al (2023) Updated Rev Hypertrophic Scarring Cells, 12(5)","DOI":"10.3390\/cells12050678"},{"issue":"1","key":"3352_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/exd.14121","volume":"30","author":"GC Limandjaja","year":"2021","unstructured":"Limandjaja GC et al (2021) Hypertrophic scars and keloids: overview of the evidence and practical guide for differentiating between these abnormal scars. Exp Dermatol 30(1):146\u2013161","journal-title":"Exp Dermatol"},{"issue":"2","key":"3352_CR3","first-page":"33","volume":"13","author":"U Betarbet","year":"2020","unstructured":"Betarbet U, Blalock TW (2020) Keloids: a review of etiology, Prevention, and treatment. J Clin Aesthet Dermatol 13(2):33\u201343","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"3352_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2340\/00015555-2498","volume":"97","author":"E Bijlard","year":"2017","unstructured":"Bijlard E et al (2017) Burden of Keloid Disease: a cross-sectional health-related quality of Life Assessment. Acta Derm Venereol 97(2):225\u2013229","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"3352_CR5","first-page":"1636","volume":"13","author":"W Lu","year":"2021","unstructured":"Lu W, Chu H, Zheng X (2021) Effects on quality of life and psychosocial wellbeing in Chinese patients with keloids. Am J Transl Res 13(3):1636\u20131642","journal-title":"Am J Transl Res"},{"key":"3352_CR6","doi-asserted-by":"crossref","unstructured":"Olopoenia A et al (2024) Demographics, clinical characteristics, and treatment patterns among keloid patients: United States Electronic Health Records (EHR) Database Study. Int J Dermatol","DOI":"10.1111\/ijd.17099"},{"key":"3352_CR7","unstructured":"Sarah McGinty WJS, Keloid (2023) [Internet] [cited September 20, 2023; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507899\/"},{"key":"3352_CR8","unstructured":"Insights FM (2023) Keloid Treatment Market Outlook (2023 to 2033). [cited June 26, 2024"},{"key":"3352_CR9","doi-asserted-by":"publisher","first-page":"603187","DOI":"10.3389\/fimmu.2020.603187","volume":"11","author":"ZC Wang","year":"2020","unstructured":"Wang ZC et al (2020) The roles of inflammation in Keloid and hypertrophic scars. Front Immunol 11:603187","journal-title":"Front Immunol"},{"key":"3352_CR10","doi-asserted-by":"publisher","first-page":"1117630","DOI":"10.3389\/fimmu.2023.1117630","volume":"14","author":"CC Lee","year":"2023","unstructured":"Lee CC et al (2023) An updated review of the immunological mechanisms of keloid scars. Front Immunol 14:1117630","journal-title":"Front Immunol"},{"issue":"5","key":"3352_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1089\/wound.2021.0161","volume":"12","author":"YK Hong","year":"2023","unstructured":"Hong YK et al (2023) Inflammation in Wound Healing and pathological scarring. Adv Wound Care (New Rochelle) 12(5):288\u2013300","journal-title":"Adv Wound Care (New Rochelle)"},{"issue":"1","key":"3352_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1272\/jnms.74.11","volume":"74","author":"M Ghazizadeh","year":"2007","unstructured":"Ghazizadeh M (2007) Essential role of IL-6 signaling pathway in keloid pathogenesis. J Nippon Med Sch 74(1):11\u201322","journal-title":"J Nippon Med Sch"},{"issue":"6","key":"3352_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.1365-2133.2011.10721.x","volume":"166","author":"DV Do","year":"2012","unstructured":"Do DV et al (2012) Interleukin-18 system plays an important role in keloid pathogenesis via epithelial\u2013mesenchymal interactions. Br J Dermatol 166(6):1275\u20131288","journal-title":"Br J Dermatol"},{"key":"3352_CR14","doi-asserted-by":"publisher","first-page":"667763","DOI":"10.3389\/fphar.2021.667763","volume":"12","author":"D Zhang","year":"2021","unstructured":"Zhang D, Li B, Zhao M (2021) Therapeutic strategies by regulating Interleukin Family to suppress inflammation in hypertrophic scar and keloid. Front Pharmacol 12:667763","journal-title":"Front Pharmacol"},{"issue":"8","key":"3352_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s12276-023-01045-6","volume":"55","author":"AR Lee","year":"2023","unstructured":"Lee AR et al (2023) Establishment of a humanized mouse model of keloid diseases following the migration of patient immune cells to the lesion: patient-derived keloid xenograft (PDKX) model. Exp Mol Med 55(8):1713\u20131719","journal-title":"Exp Mol Med"},{"key":"3352_CR16","doi-asserted-by":"crossref","unstructured":"Zhang XY, Wu XF, Li DQ (2023) The communication from Immune cells to the fibroblasts in Keloids: implications for Immunotherapy. Int J Mol Sci, 24(20)","DOI":"10.3390\/ijms242015475"},{"key":"3352_CR17","doi-asserted-by":"crossref","unstructured":"Tang Y et al (2023) Tissue RNA sequencing reveals novel biomarkers Associated with Postoperative Keloid recurrence. J Clin Med, 12(17)","DOI":"10.3390\/jcm12175511"},{"issue":"10","key":"3352_CR18","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.1111\/jocd.15009","volume":"21","author":"Q Yan","year":"2022","unstructured":"Yan Q, Li B (2022) TRAF3IP2 regulated by FOXO4 affects fibroblast proliferation, migration, and extracellular matrix deposition in keloid through the TGF-\u03b21\/Smad pathway. J Cosmet Dermatol 21(10):5148\u20135155","journal-title":"J Cosmet Dermatol"},{"issue":"10","key":"3352_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/intimm\/dxs056","volume":"24","author":"Y Liu","year":"2012","unstructured":"Liu Y et al (2012) IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKC\u03b2\/Erk1\/2\/NF-\u03baB-dependent signaling pathway. Int Immunol 24(10):605\u2013612","journal-title":"Int Immunol"},{"issue":"14","key":"3352_CR20","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/15353702231182224","volume":"248","author":"D Jiang","year":"2023","unstructured":"Jiang D et al (2023) Interleukin-17A plays a key role in pulmonary fibrosis following Propionibacterium acnes-induced sarcoidosis-like inflammation. Exp Biol Med (Maywood) 248(14):1181\u20131190","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"3352_CR21","first-page":"21","volume":"9","author":"YJ Nie","year":"2022","unstructured":"Nie YJ et al (2022) Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis. Mil Med Res 9(1):21","journal-title":"Mil Med Res"},{"issue":"3","key":"3352_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","volume":"143","author":"F Meng","year":"2012","unstructured":"Meng F et al (2012) Interleukin-17 signaling in inflammatory, kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143(3):765\u2013776e3","journal-title":"Gastroenterology"},{"key":"3352_CR23","doi-asserted-by":"crossref","unstructured":"Sisto M, Lisi S (2023) Targeting Interleukin-17 as a Novel Treatment option for Fibrotic diseases. J Clin Med, 13(1)","DOI":"10.3390\/jcm13010164"},{"key":"3352_CR24","doi-asserted-by":"publisher","first-page":"109741","DOI":"10.1016\/j.biopha.2019.109741","volume":"123","author":"CH Weng","year":"2020","unstructured":"Weng CH et al (2020) Interleukin-17A induces renal fibrosis through the ERK and Smad signaling pathways. Biomed Pharmacother 123:109741","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"3352_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/ijd.15159","volume":"60","author":"SF Ekstein","year":"2021","unstructured":"Ekstein SF et al (2021) Keloids: a review of therapeutic management. Int J Dermatol 60(6):661\u2013671","journal-title":"Int J Dermatol"},{"key":"3352_CR26","doi-asserted-by":"crossref","unstructured":"El Kinani M, Duteille F et al (2020) Scar Epidemiology and Consequences, in Textbook on Scar Management: State of the Art Management and Emerging Technologies, L. T\u00e9ot, Editors. Springer Copyright 2020, The Author(s). Cham (CH). pp. 45\u2009\u2013\u20099","DOI":"10.1007\/978-3-030-44766-3_6"},{"issue":"12","key":"3352_CR27","first-page":"e50290","volume":"15","author":"RA Al Zahrani","year":"2023","unstructured":"Al Zahrani RA et al (2023) Comprehensive Analysis of Current Treatment approaches for keloids in Pediatrics: a systematic review. Cureus 15(12):e50290","journal-title":"Cureus"},{"key":"3352_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/CCID.S35252","volume":"6","author":"GG Gauglitz","year":"2013","unstructured":"Gauglitz GG (2013) Management of keloids and hypertrophic scars: current and emerging options. Clin Cosmet Investig Dermatol 6:103\u2013114","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"3352_CR29","doi-asserted-by":"publisher","first-page":"810290","DOI":"10.3389\/fimmu.2021.810290","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y et al (2021) The polygenic map of keloid fibroblasts reveals Fibrosis-Associated gene alterations in inflammation and Immune responses. Front Immunol 12:810290","journal-title":"Front Immunol"},{"key":"3352_CR30","doi-asserted-by":"publisher","first-page":"1309992","DOI":"10.3389\/fimmu.2024.1309992","volume":"15","author":"B Zhou","year":"2024","unstructured":"Zhou B et al (2024) Identification and validation of CCR5 linking keloid with atopic dermatitis through comprehensive bioinformatics analysis and machine learning. Front Immunol 15:1309992","journal-title":"Front Immunol"},{"issue":"47","key":"3352_CR31","doi-asserted-by":"publisher","first-page":"e27777","DOI":"10.1097\/MD.0000000000027777","volume":"100","author":"W Zheng","year":"2021","unstructured":"Zheng W, Lin G, Wang Z (2021) Bioinformatics study on different gene expression profiles of fibroblasts and vascular endothelial cells in keloids. Med (Baltim) 100(47):e27777","journal-title":"Med (Baltim)"},{"key":"3352_CR32","doi-asserted-by":"publisher","first-page":"597741","DOI":"10.3389\/fimmu.2020.597741","volume":"11","author":"J Wu","year":"2020","unstructured":"Wu J et al (2020) RNA sequencing keloid Transcriptome associates Keloids with Th2, Th1, Th17\/Th22, and JAK3-Skewing. Front Immunol 11:597741","journal-title":"Front Immunol"},{"key":"3352_CR33","first-page":"14","volume":"15","author":"B Zhou","year":"2024","unstructured":"Zhou B et al (2024) Identification and validation of CCR5 linking keloid with atopic dermatitis through comprehensive bioinformatics analysis and machine learning. Front Immunol 15:14","journal-title":"Front Immunol"},{"issue":"11","key":"3352_CR34","doi-asserted-by":"publisher","first-page":"e7798","DOI":"10.1371\/journal.pone.0007798","volume":"4","author":"Q Zhang","year":"2009","unstructured":"Zhang Q et al (2009) Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17\/IL-6 axis. PLoS ONE 4(11):e7798","journal-title":"PLoS ONE"},{"issue":"2","key":"3352_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jid.2018.07.044","volume":"139","author":"M Fujita","year":"2019","unstructured":"Fujita M et al (2019) NEDD4 is involved in inflammation development during keloid formation. J Invest Dermatol 139(2):333\u2013341","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3352_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/scrt39","volume":"1","author":"G Shi","year":"2010","unstructured":"Shi G, Jin Y (2010) Role of Oct4 in maintaining and regaining stem cell pluripotency. Stem Cell Res Ther 1(5):39","journal-title":"Stem Cell Res Ther"},{"key":"3352_CR37","first-page":"e15","volume":"11","author":"M Granick","year":"2011","unstructured":"Granick M et al (2011) Telomere dynamics in keloids. Eplasty 11:e15","journal-title":"Eplasty"},{"issue":"4","key":"3352_CR38","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/art.22439","volume":"56","author":"KW Kim","year":"2007","unstructured":"Kim KW et al (2007) Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum 56(4):1076\u20131086","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3352_CR39","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s10753-019-01148-1","volume":"43","author":"SY Lee","year":"2020","unstructured":"Lee SY et al (2020) IL-17 Induced Stromal Cell-Derived Factor-1 and profibrotic factor in keloid-derived skin fibroblasts\u2009<\u2009i\u2009>\u2009via the STAT3 pathway. Inflammation 43(2):664\u2013672","journal-title":"Inflammation"},{"issue":"3","key":"3352_CR40","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2353\/ajpath.2010.090850","volume":"176","author":"L Kohli","year":"2010","unstructured":"Kohli L, Roth KA (2010) Autophagy Am J Pathol 176(3):1065\u20131071","journal-title":"Autophagy Am J Pathol"},{"key":"3352_CR41","first-page":"9","volume":"13","author":"SY Lee","year":"2022","unstructured":"Lee SY et al (2022) IL-17 induces Autophagy Dysfunction to promote inflammatory cell death and fibrosis in keloid fibroblasts\u2009<\u2009i\u2009>\u2009via the STAT3 and HIF-1a Dependent Signaling pathways. Front Immunol 13:9","journal-title":"Front Immunol"},{"issue":"8","key":"3352_CR42","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/lsm.23579","volume":"54","author":"S Li","year":"2022","unstructured":"Li S et al (2022) Relative perfusion index: an objective, quantitative and noninvasive method for evaluating the severity of keloids. Lasers Surg Med 54(8):1071\u20131081","journal-title":"Lasers Surg Med"},{"key":"3352_CR43","doi-asserted-by":"publisher","first-page":"888719","DOI":"10.3389\/fimmu.2022.888719","volume":"13","author":"SY Lee","year":"2022","unstructured":"Lee SY et al (2022) IL-17 induces Autophagy Dysfunction to promote inflammatory cell death and fibrosis in keloid fibroblasts via the STAT3 and HIF-1\u03b1 Dependent Signaling pathways. Front Immunol 13:888719","journal-title":"Front Immunol"},{"issue":"2","key":"3352_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cge.13767","volume":"98","author":"G Nemer","year":"2020","unstructured":"Nemer G et al (2020) A novel TRAF3IP2 variant causing familial scarring alopecia with mixed features of discoid lupus erythematosus and folliculitis decalvans. Clin Genet 98(2):116\u2013125","journal-title":"Clin Genet"},{"key":"3352_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.yjmcc.2018.07.003","volume":"121","author":"NA Das","year":"2018","unstructured":"Das NA et al (2018) TRAF3IP2 mediates TWEAK\/TWEAKR-induced pro-fibrotic responses in cultured cardiac fibroblasts and the heart. J Mol Cell Cardiol 121:107\u2013123","journal-title":"J Mol Cell Cardiol"},{"issue":"12","key":"3352_CR46","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1016\/j.celrep.2019.07.039","volume":"28","author":"TSC Hinks","year":"2019","unstructured":"Hinks TSC et al (2019) Activation and in vivo evolution of the MAIT Cell Transcriptome in mice and humans reveals tissue repair functionality. Cell Rep 28(12):3249\u20133262e5","journal-title":"Cell Rep"},{"issue":"2","key":"3352_CR47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/exd.14700","volume":"32","author":"Y Nurzat","year":"2023","unstructured":"Nurzat Y et al (2023) Invariant chain of the MAIT-TCR v\u03b17.2-J\u03b133 as a novel diagnostic biomarker for keloids. Exp Dermatol 32(2):186\u2013197","journal-title":"Exp Dermatol"},{"issue":"2","key":"3352_CR48","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s10753-019-01148-1","volume":"43","author":"SY Lee","year":"2020","unstructured":"Lee SY et al (2020) IL-17 Induced Stromal cell\u2013derived Factor-1 and profibrotic factor in keloid-derived skin fibroblasts via the STAT3 pathway. Inflammation 43(2):664\u2013672","journal-title":"Inflammation"},{"issue":"4\u20135","key":"3352_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"E Suzuki","year":"2014","unstructured":"Suzuki E et al (2014) The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev 13(4\u20135):496\u2013502","journal-title":"Autoimmun Rev"},{"key":"3352_CR50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.atherosclerosis.2016.05.029","volume":"252","author":"S Sakamuri","year":"2016","unstructured":"Sakamuri S et al (2016) TRAF3IP2 mediates atherosclerotic plaque development and vulnerability in ApoE(-\/-) mice. Atherosclerosis 252:153\u2013160","journal-title":"Atherosclerosis"},{"issue":"51","key":"3352_CR51","doi-asserted-by":"publisher","first-page":"29772","DOI":"10.18632\/oncotarget.25710","volume":"9","author":"EU Alt","year":"2018","unstructured":"Alt EU et al (2018) TRAF3IP2, a novel therapeutic target in glioblastoma multiforme. Oncotarget 9(51):29772\u201329788","journal-title":"Oncotarget"},{"key":"3352_CR52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cbi.2018.07.008","volume":"292","author":"HH Hu","year":"2018","unstructured":"Hu HH et al (2018) New insights into TGF-\u03b2\/Smad signaling in tissue fibrosis. Chem Biol Interact 292:76\u201383","journal-title":"Chem Biol Interact"},{"key":"3352_CR53","doi-asserted-by":"publisher","first-page":"1331217","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger JG et al (2024) IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol 15:1331217","journal-title":"Front Immunol"},{"issue":"9","key":"3352_CR54","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.4049\/jimmunol.1002860","volume":"187","author":"LA Cooney","year":"2011","unstructured":"Cooney LA et al (2011) Sensitivity and resistance to regulation by IL-4 during Th17 maturation. J Immunol 187(9):4440\u20134450","journal-title":"J Immunol"},{"issue":"3","key":"3352_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y et al (2022) Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18(3):133\u2013145","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"3352_CR56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/cts.13435","volume":"16","author":"IM Catlett","year":"2023","unstructured":"Catlett IM et al (2023) First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin Transl Sci 16(1):151\u2013164","journal-title":"Clin Transl Sci"},{"key":"3352_CR57","doi-asserted-by":"crossref","unstructured":"Sakai R et al (2024) Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database. RMD Open, 10(2)","DOI":"10.1136\/rmdopen-2023-003885"},{"issue":"6","key":"3352_CR58","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s10067-024-06980-x","volume":"43","author":"MAA Opdam","year":"2024","unstructured":"Opdam MAA et al (2024) Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clin Rheumatol 43(6):2133\u20132138","journal-title":"Clin Rheumatol"},{"issue":"2","key":"3352_CR59","doi-asserted-by":"publisher","first-page":"197","DOI":"10.36849\/JDD.6252","volume":"21","author":"K Luk","year":"2022","unstructured":"Luk K, Fakhoury J, Ozog D (2022) Nonresponse and progression of diffuse keloids to Dupilumab Therapy. J Drugs Dermatol 21(2):197\u2013199","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"3352_CR60","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1111\/jdv.17669","volume":"36","author":"MH Tirgan","year":"2022","unstructured":"Tirgan MH, Uitto J (2022) Lack of efficacy of dupilumab in the treatment of keloid disorder. J Eur Acad Dermatol Venereol 36(2):e120\u2013e122","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"3352_CR61","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.36849\/JDD.6385","volume":"22","author":"MS Min","year":"2023","unstructured":"Min MS et al (2023) Successful treatment of keloids and hypertrophic scars with systemic and Intralesional Dupilumab. J Drugs Dermatol 22(12):1220\u20131222","journal-title":"J Drugs Dermatol"},{"key":"3352_CR62","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jdcr.2023.05.001","volume":"37","author":"A Wittmer","year":"2023","unstructured":"Wittmer A, Finklea L, Joseph J (2023) Effects of dupilumab on keloid stabilization and prevention. JAAD Case Rep 37:103\u2013105","journal-title":"JAAD Case Rep"},{"key":"3352_CR63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jdcr.2021.04.034","volume":"13","author":"AJS Wong","year":"2021","unstructured":"Wong AJS, Song EJ (2021) Dupilumab as an adjuvant treatment for keloid-associated symptoms. JAAD Case Rep 13:73\u201374","journal-title":"JAAD Case Rep"},{"issue":"4","key":"3352_CR64","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1111\/jdv.16097","volume":"34","author":"A Diaz","year":"2020","unstructured":"Diaz A et al (2020) Keloid lesions show increased IL-4\/IL-13 signaling and respond to Th2-targeting dupilumab therapy. J Eur Acad Dermatol Venereol 34(4):e161\u2013e164","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3352_CR65","unstructured":"ClinicalTrials.gov. NCT04988022: Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Keloid (2024) 2024\/06\/26] ; https:\/\/clinicaltrials.gov\/study\/NCT04988022?cond=Keloid%20dupilumab&rank=1"},{"issue":"5","key":"3352_CR66","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1159\/000532064","volume":"239","author":"JY Chen","year":"2023","unstructured":"Chen JY et al (2023) An Open-Label, uncontrolled, single-arm clinical trial of Tofacitinib, an oral JAK1 and JAK3 kinase inhibitor, in Chinese patients with Keloid. Dermatology 239(5):818\u2013827","journal-title":"Dermatology"},{"issue":"1","key":"3352_CR67","doi-asserted-by":"publisher","first-page":"79e","DOI":"10.1097\/PRS.0000000000008667","volume":"149","author":"R Ogawa","year":"2022","unstructured":"Ogawa R (2022) The most current algorithms for the Treatment and Prevention of Hypertrophic Scars and keloids: a 2020 update of the algorithms published 10 years ago. Plast Reconstr Surg 149(1):79e\u201394e","journal-title":"Plast Reconstr Surg"},{"key":"3352_CR68","doi-asserted-by":"publisher","first-page":"205951311989111","DOI":"10.1177\/2059513119891113","volume":"5","author":"R Ogawa","year":"2019","unstructured":"Ogawa R et al (2019) Surgical excision and postoperative radiotherapy for keloids. Scars Burn Heal 5:2059513119891113","journal-title":"Scars Burn Heal"},{"issue":"3","key":"3352_CR69","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/s-0029-1224797","volume":"23","author":"CJ Chike-Obi","year":"2009","unstructured":"Chike-Obi CJ, Cole PD, Brissett AE (2009) Keloids: pathogenesis, clinical features, and management. Semin Plast Surg 23(3):178\u2013184","journal-title":"Semin Plast Surg"},{"key":"3352_CR70","unstructured":"Drugs.com. Cosentyx: History (2024) \/06\/26] ; https:\/\/www.drugs.com\/history\/cosentyx.html"},{"key":"3352_CR71","unstructured":"Drugs.com. Taltz: History (2024) \/06\/26] ; https:\/\/www.drugs.com\/history\/taltz.html"},{"key":"3352_CR72","unstructured":"Drugs.com. Bimzelx: History (2024) \/06\/26] ; https:\/\/www.drugs.com\/history\/bimzelx.html"},{"key":"3352_CR73","unstructured":"Drugs.com. Siliq: History (2024) \/06\/26] ; https:\/\/www.drugs.com\/history\/siliq.html"},{"key":"3352_CR74","unstructured":"Drugs.com. Stelara: History (2024) \/06\/26] ; https:\/\/www.drugs.com\/history\/stelara.html"},{"key":"3352_CR75","unstructured":"Drugs.com. Tremfya: History (2024) \/06\/26] ; https:\/\/www.drugs.com\/history\/tremfya.html"},{"key":"3352_CR76","unstructured":"Drugs.com. Ilumya: History (2024) \/06\/26] ; https:\/\/www.drugs.com\/history\/ilumya.html"},{"key":"3352_CR77","unstructured":"Drugs.com. Skyrizi: History (2024) \/06\/26] ; https:\/\/www.drugs.com\/history\/skyrizi.html"},{"key":"3352_CR78","unstructured":"Drugs.com. Actemra: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/actemra.html"},{"key":"3352_CR79","unstructured":"Drugs.com. Kevzara: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/kevzara.html"},{"key":"3352_CR80","unstructured":"Drugs.com. Enspryng: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/enspryng.html"},{"key":"3352_CR81","unstructured":"Drugs.com. Sylvant: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/sylvant.html"},{"key":"3352_CR82","unstructured":"Drugs.com. Xeljanz: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/xeljanz.html"},{"key":"3352_CR83","unstructured":"Drugs.com. Olumiant: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/olumiant.html"},{"key":"3352_CR84","unstructured":"Drugs.com. Jakafi: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/jakafi.html"},{"key":"3352_CR85","unstructured":"Drugs.com. Opzelura: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/opzelura.html"},{"key":"3352_CR86","unstructured":"Drugs.com. Leqselvi: History (2024) \/08\/04] ; https:\/\/www.drugs.com\/history\/leqselvi.html"},{"key":"3352_CR87","unstructured":"Drugs.com. Rinvoq: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/rinvoq.html"},{"key":"3352_CR88","unstructured":"Drugs.com. Cibinqo: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/cibinqo.html"},{"key":"3352_CR89","unstructured":"Drugs.com. Sotyktu: History (2024) \/06\/27] ; https:\/\/www.drugs.com\/history\/sotyktu.html"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03352-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T14:03:05Z","timestamp":1729864985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03352-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":89,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["3352"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03352-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"626"}}